

2600MO

Relevance of the CPS score and tumor nephrectomy in the SUNNIFORECAST trial comparing ipilimumab/nivolumab versus standard of care in non-clear cell renal cell cancer

L. Bergmann¹, L. Albiges², M. Ahrens³, M. Gross Goupil⁴, E. Boleti⁵, G. Gravis⁶, A. Flechon⁷, M-O. Grimm⁸, J. Bedke⁹, P. Barthelemy¹⁰, D.E. Castellano Gauna¹¹, B. Mellado Gonzalez¹², P. Ivanyi¹³, A. Floercken¹⁴, C. Suarez Rodriguez¹⁵, J.P. Maroto Rey¹⁶, V. Gruenwald¹⁷, I. Burkholder¹⁸, A. Hartmann¹⁹, J.B.A.G. Haanen²⁰

¹ Medical Clinic II, Oncology, Universitätsklinikum Frankfurt (Johannes-Wolfgang Goethe Institute), Frankfurt am Main, Germany, ² Medical Oncology Department, Institut Gustave Roussy, Villejuif, France, ³ Medical Clinic II, Universitätsklinikum Frankfurt (Johannes-Wolfgang Goethe-Universität), Frankfurt am Main, Germany, ⁴ Medical Oncology, CHU Bordeaux - Hopital St. André, Bordeaux, France, ⁵ Academic Oncology Department, Royal Free Hospital School of Medicine, London, United Kingdom, ⁶ Medical Oncology Dept., IPC - Institut Paoli-Calmettes, Marseille, France, ⁷ Medical Oncology, Centre Léon Bérard, Lyon, France, ⁸ Urology Department, Universitaetsklinikum Jena - Klinik für Innere Medizin II, Jena, Germany, ⁹ Urology Dept., Klinikum Stuttgart - Katharinenhospital (KH), Stuttgart, Germany, ¹⁰ Medical Oncology Department, ICANS - Institut de Cancérologie Strasbourg Europe, Strasbourg, France, ¹¹ Medical Oncology Department, Hospital Universitario 12 de Octubre, Madrid, Spain, ¹² Medical Oncology Dept., Hospital Clinic y Provincial de Barcelona, Barcelona, Spain, ¹³ Hematology, Hemostasis, Oncology & Stem Cell Transpl. Dept, MHH - Medizinische Hochschule Hannover, Hannover, Germany, ¹⁴ Hematology, Oncology, and Tumor Immunology, Universitätsklinik Charité - Campus Virchow Klinikum, Berlin, Germany, ¹⁵ Oncology Dept., Vall d'Hebron University Hospital, Barcelona, Spain, ¹⁶ Medical Oncology Department, Hospital de la Santa Creu i Sant Pau, Barcelona, Spain, ¹⁷ Clinic for Cancer Research and Clinic for Urology, WTZ - Westdeutsches Tumorzentrum Essen, Essen, Germany, ¹⁸ Fachbereich Gesundheitswissenschaften / Department of Health Sciences, Hochschule Fulda, Fulda, Germany, ¹⁹ Pathology Department, Universitätsklinik Erlangen, Erlangen, Germany, ²⁰ Medical Oncology Dept, NKI-AVL - Netherlands Cancer Institute/Antoni van Leeuwenhoek Hospital, Amsterdam, Netherlands

Background

Non-clear cell renal cancers (nccRCC) are a rare and heterogeneous group of more than 20 histological and molecular defined entities. So far, TKI therapy with or without immune checkpoint inhibitors (ICI) are considered standard of care (SOC) options in these diseases, but the data are sparse. Here, we report results of the academic prospective randomised European trial in therapy-naïve patients with advanced nccRCC entities, which compared ipilimumab/nivolumab (Ipi/Nivo) vs SOC (SUNNIFORECAST trial).

Methods

We randomly assigned patients (pts) with nccRCC in a 1:1 ratio to receive either nivolumab 3 mg/kg IV combined with ipilimumab 1 mg/kg IV every 3 weeks for 4 doses followed by a flat dose of 240 mg IV every 2 weeks or 480 mg every 4 weeks versus SOC by investigators choice. Patients were stratified in papillary vs. non-papillary nccRCC and according to IMDC risk score. The primary endpoint was the OS rate at 12 months (mos), secondary endpoints were the OS rate at 6 mos and 18 mos, OS, PFS and ORR.

Results

In total, 309 pts were randomized to receive either Ipi/Nivo or SOC (124 TKI, 17 TKI/IO). The 12 mos OS rate for Ipi/Nivo of 78.3% vs 68.3% in the SOC arm was significantly superior ($p=0.026$). Median OS was 33.2 mos for the Ipi/Nivo arm and 25.2 mos for the SOC arm. The CPS differed between the various subentities considerably and was associated with the outcome. The ORR in patients with CPS >1 was 43.3% but with CPS <1 only 22.2% in the Ipi/Nivo arm. There was no difference between the CPS levels in the SOC arm with an ORR of 19.6% and 19.1%. Pts with a CPS >1 had an OS-rate at 12-months of 83.5% in the Ipi/Nivo arm vs 57.6% and a median OS of 40.8 mos vs. 22.2 mos ($p=0.008$). Additionally, pts who underwent nephrectomy had a longer median OS in general with 38.5 mos in the Ipi/Nivo arm vs. 33.9 mos in the SOC arm, the benefit of Ipi/Nivo, however, was more pronounced in those who did not undergo tumor nephrectomy with 26.3 mos vs 16.5 mos ($p=0.065$).

Conclusions

The primary endpoint (OS rate at 12mos) was met in favour of ipilimumab/ nivolumab. A CPS-score >1 predicts a better outcome with Ipi/Nivo compared to those with a CPS <1 and the SOC arm. In pts. without nephrectomy, Ipi/Nivo seems to be more effective than SOC for OS.

Clinical trial identification

2016-000706-12; NCT03075423.

Legal entity responsible for the study

Goethe University Frankfurt.

Funding

The study was supported by a grant of BMS.

Disclosure

L. Albiges: Financial Interests, Institutional, Other, Consulting: Astellas, BMS, Eisai, Ipsen, Janssen, MSD, Novartis, Pfizer, Roche, Merck, Amgen, Daiichi Sankyo, Xencor, Telix Pharmaceuticals; Financial Interests, Institutional, Other, Honoraria: Novartis; Non-Financial Interests, Principal Investigator, Clinical trial steering committee: Pfizer, BMS, AVEO, AstraZeneca, MSD; Non-Financial Interests, Principal Investigator: Ipsen; Non-Financial Interests, Other, Clinical trial steering committee: Roche, Exelixis, Telix Pharmaceuticals; Non-Financial Interests, Member: ASCO; Non-Financial Interests, Other, Medical Steering Committee: Kidney Cancer Association; Non-Financial Interests, Other, Member of the Renal Cell Carcinoma Guidelines Panel: European Association of Urology (EAU). M. Ahrens: Financial Interests, Advisory Board: BMS, Eisai, Ipsen, Merck, Pfizer. M. Gross Goupil: Financial Interests, Personal, Advisory Board: AstraZeneca, BMS, Astellas, MSD, Ipsen, Eisai, Pfizer, Eisai, Pfizer, Astellas; Financial Interests, Personal, Invited Speaker: BMS, Astellas, Amgen, MSD, Janssen, Eisai, BMS; Financial Interests, Personal, Invited Speaker, symposium during national congress: Merck, BMS; Financial Interests, Personal, Invited Speaker, slides on criteria of choice of treatment for kidney cancer - during a national meeting: Ipsen; Financial Interests, Personal, Invited Speaker, MSD standalone: MSD; Financial Interests, Personal, Invited Speaker, ArTUR congress -Ipsen symposium: Ipsen; Financial Interests, Personal, Invited Speaker, Avenir: Merck; Financial Interests, Personal, Advisory Board, EV-pembro / access: Astellas; Financial Interests, Personal, Advisory Board, EV-Pembro/ access: MSD; Financial Interests, Personal, Invited Speaker, ROUSO: Bayer; Financial Interests, Institutional, Coordinating PI: Pfizer; Financial Interests, Institutional, Steering Committee Member, clinical trial: Roche; Non-Financial Interests, Principal Investigator: Pfizer, Ipsen, Gilead, Roche, Bayer, Astellas, Janssen, BMS, Msd, AstraZeneca. G. Gravis: Financial Interests, Personal, Other, Support for attending meetings and/or travel: AAA Novartis, AstraZeneca, BMS, Bayer, MSD; Financial Interests, Institutional, Invited Speaker: AAA Novartis, AMGEN, ASTRAZENECA, BMS, Bayer, IPSEN, Janssen, MSD; Financial Interests, Personal, Other, support for travel: Amgen; Financial Interests, Institutional, Advisory Board: Astellas, AstraZeneca, BMS, Bayer, Eisai, Gilead, Janssen, PFIZER, Ipsen, curium; Financial Interests, Institutional, Other, Steering committee member: Novartis; Non-Financial Interests, Principal Investigator: IPSEN, BMS, Merck. J. Bedke: Financial Interests, Personal, Advisory Board: AstraZeneca, Astellas, Eisai; Financial Interests, Personal, Advisory Board, Advisory Board and Speaker's Bureau: BMS, Ipsen, MSD, Merck Sorono, Pfizer, Roche, Janssen; Financial Interests, Institutional, Advisory Board: Pfizer; Financial Interests, Institutional, Local PI: AstraZeneca, Eisai, Novartis, Nektar; Financial Interests, Institutional, Coordinating PI: Astellas, BMS, MSD, Ipsen, Pfizer, Roche, Seagen; Financial Interests, Institutional, Steering Committee Member: BMS, MSD, Pfizer, Seagen; Other, Other, Member of the Renal Cell Carcinoma Guidelines Panel: European Association of Urology. C. Suarez Rodriguez: Financial Interests, Personal, Invited Speaker: Astellas Pharma, Bristol Myers Squibb (Inst), IPSEN, Hoffmann-La Roche LTD, Merck; Financial Interests, Personal, Advisory Board: Bristol Myers Squibb (Inst), Ipsen, Hoffmann-La Roche LTD, Merck Sharp and Dohme, Eisai; Financial Interests, Institutional, Funding: Ipsen; Financial Interests, Institutional, Research Grant: Pfizer. J.P. Maroto Rey: Financial Interests, Personal, Advisory Board, Participation in Ad boards: Bayer; Financial Interests, Personal, Advisory Board, Participation in ad boards: Astellas, Merck, Pfizer, MSD; Financial Interests, Personal, Invited Speaker: Janssen; Non-Financial Interests, Principal Investigator, Collaboration as PI in trials: AstraZeneca. All other authors have declared no conflicts of interest.

© European Society for Medical Oncology